Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | TTK | P33981 | 2/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.48 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.46 |
| ▸ | MAP3K5 | Q99683 | 5/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.44 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5378125 | 0.89 | CSNK1D (0.56) | TTKMAPK8MAP2K4CSNK1DMAP3K5 | |
| SCHEMBL8258720 | 0.87 | LRRK2 (0.52) | DYRK1ATTKMAPK8MAP2K4CSNK1D | |
| SCHEMBL17801052 | 0.86 | TTK (0.53) | TTKMAPK8MAP2K4CSNK1DMAP3K5 | |
| SCHEMBL5375633 | 0.84 | MAP3K5 (0.54) | TTKMAPK8MAP2K4CSNK1DMAP3K5 | |
| SCHEMBL5372266 | 0.84 | MAP2K4 (0.63) | TTKMAPK8MAP2K4CSNK1DMAP3K5 | |
| SCHEMBL8254966 | 0.84 | AURKA (0.56) | JAK2DYRK1ATTKMAPK8MAP2K4 | |
| SCHEMBL8257261 | 0.83 | MAP3K5 (0.65) | TTKMAPK8MAP2K4CSNK1DMAP3K5 | |
| SCHEMBL5380225 | 0.83 | CSNK1D (0.56) | DYRK1ATTKMAPK8MAP2K4CSNK1D | |
| SCHEMBL8252590 | 0.83 | CSNK1D (0.54) | DYRK1ATTKMAPK8MAP2K4CSNK1D | |
| SCHEMBL8257307 | 0.83 | MAP3K5 (0.61) | DYRK1AMAPK8MAP2K4MAP3K5MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170327788-A1 | COMPOSITION FOR COLLECTING AND PRESERVING PLACENTAL STEM CELLS AND METHODS OF USING THE COMPOSITION | ANTHROGENESIS CORPORATION (US) | 2017-11-16 | — | — | US | disclosed |
| US-9725694-B2 | Composition for collecting and preserving placental stem cells and methods of using the composition | ANTHROGENESIS CORPORATION (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725694-B2 | Composition for collecting and preserving placental stem cells and methods of using the composition | ANTHROGENESIS CORPORATION (US) | 2017-08-08 | — | — | US | disclosed |
| US-20100291679-A1 | COMPOSITION FOR COLLECTING AND PRESERVING PLACENTAL STEM CELLS AND METHODS OF USING THE COMPOSITION | ANTHROGENESIS CORPORATION | 2010-11-18 | — | — | US | disclosed |
| US-20100291679-A1 | COMPOSITION FOR COLLECTING AND PRESERVING PLACENTAL STEM CELLS AND METHODS OF USING THE COMPOSITION | ANTHROGENESIS CORPORATION | 2010-11-18 | — | — | US | disclosed |
| WO-2008091925-A2 | TREATMENT OF AORTIC DISSECTION OR ANEURYSM | COOK INCORPORATED (US) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008091925-A2 | TREATMENT OF AORTIC DISSECTION OR ANEURYSM | COOK INCORPORATED (US) | 2008-07-31 | — | — | WO | disclosed |
| US-20070270448-A1 | Methods of Using and Compositions Comprising a Jnk Inhibitor for the Treatment and Management of Asbestos-Related Diseases and Disorders | CELGENE CORPORATION (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070270448-A1 | Methods of Using and Compositions Comprising a Jnk Inhibitor for the Treatment and Management of Asbestos-Related Diseases and Disorders | CELGENE CORPORATION (US) | 2007-11-22 | — | — | US | disclosed |
| EP-1827422-A2 | JNK INHIBITORS FOR THE TREATMENT OF CNS INJURY | CELGENE CORPORATION (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006058007-A2 | JNK INHIBITORS FOR TREATMENT OF CNS INJURY | CELGENE CORPORATION (US) | 2006-06-01 | — | — | WO | disclosed |
| WO-2006058007-A2 | JNK INHIBITORS FOR TREATMENT OF CNS INJURY | CELGENE CORPORATION (US) | 2006-06-01 | — | — | WO | disclosed |
| CN-1668299-A | Methods for using JNK inhibitors for treating or preventing disease-related wasting | SIGNAL PHARM INC (US) | 2005-09-14 | — | — | CN | disclosed |
| EP-1525308-A2 | METHODS OF USING JNK OR MKK INHIBITORS TO MODULATE CELL DIFFERENTIATION AND TO TREAT MYELOPROLIFERATIVE DISORDERS AND MYELODYSPLASTIC SYNDROMES | CELGENE CORPORATION (US) | 2005-04-27 | — | — | EP | disclosed |
| WO-2004041191-A2 | METHODS FOR THE TREATMENT, PREVENTION AND MANAGEMENT OF MACULAR DEGENERATION | CELGENE CORPORATION (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040087642-A1 | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain | CELGENE CORPORATION | 2004-05-06 | — | — | US | disclosed |
| US-20040087642-A1 | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain | CELGENE CORPORATION | 2004-05-06 | — | — | US | disclosed |
| WO-2003102151-A2 | MODULATING CELL DIFFERENTIATION AND TREATING MYELOPROLIFERTIVE DISORDERS WITH JNK/MKK INHIBITORS | CELGENE CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003102151-A2 | MODULATING CELL DIFFERENTIATION AND TREATING MYELOPROLIFERTIVE DISORDERS WITH JNK/MKK INHIBITORS | CELGENE CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003099221-A2 | METHODS FOR USING JNK INHIBITORS FOR TREATING OR PREVENTING DISEASE-RELATED WASTING | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087642-A1 | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain | MAP3K1, MAP3K6, MAPKAPK2 | JAK2 236/4885DYRK1A 769/4885TTK 184/4885 |
| US-20070270448-A1 | Methods of Using and Compositions Comprising a Jnk Inhibitor for the Treatment and Management of Asbestos-Related Diseases and Disorders | MAP3K6, MAP3K1, MAPK1 | JAK2 406/4885DYRK1A 404/4885TTK 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.